13.90
+0.31(+2.28%)
Currency In USD
| Previous Close | 13.59 |
| Open | 13.62 |
| Day High | 13.97 |
| Day Low | 13.3 |
| 52-Week High | 29.56 |
| 52-Week Low | 11.9 |
| Volume | 577,553 |
| Average Volume | 740,956 |
| Market Cap | 1.05B |
| PE | -4.93 |
| EPS | -2.82 |
| Moving Average 50 Days | 17.9 |
| Moving Average 200 Days | 20.92 |
| Change | 0.31 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $731.19 as of March 12, 2025 at a share price of $13.9. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $1,074.19 as of March 12, 2025 at a share price of $13.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Feb 14, 2025 9:01 PM GMT
SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next fro
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 04, 2025 12:00 PM GMT
SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next fro
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
GlobeNewswire Inc.
Jan 22, 2025 12:00 PM GMT
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinibSAN FRANCISCO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeuti